The MONDO definition states that hypoparathyroidism may be caused by injury to the parathyroid glands, for example during surgery. Other causes named in the definition include low blood magnesium levels, a side effect of radioactive iodine treatment for hyperthyroidism, metabolic alkalosis, DiGeorge syndrome, and type I polyglandular autoimmune syndrome. The packet lists no associated genes and no inheritance patterns, so a genetic basis and mode of inheritance are not certified here, although one listed subtype is named hereditary hypoparathyroidism.

Diagnostic methods, criteria, and newborn screening information are not certified in this packet.

The MONDO definition states that the goal of treatment is to restore the calcium and mineral balance in the body. The packet's FDA-approved treatment records list three products with market status ACTIVE: Yorvipath (palopegteriparatide, NDA, approved 2024-08-09), Natpara (parathyroid hormone, BLA, approved 2015-01-23), and Drisdol (ergocalciferol, NDA, approved 1941-01-11). Orphan drug records list Yorvipath and Natpara with an indication of treatment of hypoparathyroidism. Several other agents appear in orphan drug records with status DESIGNATED, and one synthetic human parathyroid hormone 1-34 record has status WITHDRAWN; orphan designation does not indicate approval or availability, and these entries are not current approved options. Supportive care approaches are not certified in this packet.

Prognosis and natural history are not certified in this packet.

The packet reports ClinicalTrials.gov records for hypoparathyroidism. Examples include NCT07081997, a phase 3 trial of palopegteriparatide in adults sponsored by Ascendis Pharma Bone Diseases A/S (recruiting, start 2026-05-07); NCT07699471, a phase 3 study of canvuparatide versus placebo in adults sponsored by MBX Biosciences (recruiting, start 2026-08-26), and NCT07857460, the German Hypoparathyroidism Registry sponsored by University Hospital Augsburg (recruiting, start 2021-07-06). The packet also lists the patient organization Hypoparathyroidism Association (hypopara.org).